Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000759287 | SCV000289329 | benign | not provided | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000226840 | SCV000489720 | likely benign | Colorectal cancer, susceptibility to, 12 | 2016-11-10 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000603287 | SCV000713986 | likely benign | not specified | 2017-10-25 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000759287 | SCV000888526 | benign | not provided | 2018-04-26 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002258852 | SCV002536811 | benign | Hereditary cancer-predisposing syndrome | 2021-01-07 | criteria provided, single submitter | curation | |
KCCC/NGS Laboratory, |
RCV000226840 | SCV004017062 | benign | Colorectal cancer, susceptibility to, 12 | 2023-07-07 | criteria provided, single submitter | clinical testing | |
Center for Genomic Medicine, |
RCV000603287 | SCV004027333 | likely benign | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004541431 | SCV004759785 | likely benign | POLE-related disorder | 2020-01-13 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Department of Pathology and Laboratory Medicine, |
RCV001356287 | SCV001551414 | likely benign | Familial ovarian cancer | no assertion criteria provided | clinical testing | The POLE c.3378+7G>T variant was not identified in the literature. The variant was identified in dbSNP (rs755370377) as “with other allele” and ClinVar (interpreted as "benign" by Invitae and Quest Diagnostics and "likely benign" by GeneDx and Counsyl). The variant was identified in control databases in 30 of 277,184 chromosomes at a frequency of 0.0001 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European in 4 of 126,694 chromosomes (freq: 0.00003), Ashkenazi Jewish in 25 of 10,150 chromosomes (freq: 0.002), and South Asian in 1 of 30,778 chromosomes (freq: 0.00003). The variant was not observed in the African, Other, Latino, East Asian and Finnish populations. The variant occurs at a non-conserved nucleotide outside of the consensus splicing sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) did not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. |